ArticleResearch and practice in thrombosis and haemostasis2021

Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety.

Johnny Mahlangu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.